GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO-Reference-Cited by-同舟云学术

GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO

Published:2017 Issue:3 Volume:10 Page:294-316
ISSN:1997-6933
Container-title:Clinical oncohematology
language:
Short-container-title:Клиническая онкогематология

Author:

Turkina A.G.¹^ORCID,Zaritskii A.Yu.²,Shuvaev V.A.³,Chelysheva E.Yu.¹^ORCID,Lomaia E.G.²^ORCID,Morozova E.V.⁴⁵,Golenkov A.K.⁶,Pospelova T.I.⁷,Shukhov O.A.¹^ORCID,Fominykh M.S.³^ORCID,Gusarova G.A.¹,Kuz'mina L.A.¹^ORCID,Abdullaev A.O.¹^ORCID,Martynkevich I.S.³

Affiliation:

1. Hematology Research Center

2. Federal Almazov North-West Medical Research Centre

3. Russian Research Institute of Hematology and Transfusiology

4. RM Gorbacheva Scientific Research Institute of Pediatric Hematology and Transplantation

5. Pavlov First Saint Petersburg State Medical University

6. N.F. Vladimirskii Moscow Regional Research Clinical Institute

7. Novosibirsk State Medical University

Abstract

This article is the 4th edition of the recommendations for the diagnosis and treatment of chronic myeloid leukemia. The group of authors reviewed and discussed relevant new publications, and included the significant remarks and comments of experts. Particular attention was paid to the control of risk factors for the development of arterial vascular events and their prevention, and adverse effects of the longterm therapy with tyrosine kinase inhibitors, which were being increasingly reported in recent years.

Publisher

Practical Medicine Publishing House

Subject

Oncology,Hematology

Reference90 articles.

1. Куликов С.М., Виноградова О.Ю., Челышева ЕЮ. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009-2012 гг. Терапевтический архив. 2014; 86(7): 24-30

2. Туркина А.Г., Голенков А.К., Напсо Л.И. и др. Российский регистр по лечению хронического миелоидного лейкоза в рутинной клинической практике: итоги многолетней работы. Эффективная фармакотерапия. 2015; 10: 8-13

3. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96(10): 3343-56.

4. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003; 138(10): 819-30. doi: 10.7326/0003-4819-138-10-200305200-00010.

5. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009; 114(22): 462.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of morbidity and results of chronic myeloid leukemia treatment in Novosibirsk and the Novosibirsk region;Russian journal of hematology and transfusiology;2023-05-12

2. Observation in a treatment-free remission in chronic myeloid leukemia patients with a stable deep molecular response in the Russian portion of the international multicenter population based study EUTOS PBS;Russian journal of hematology and transfusiology;2022-10-22

3. Efficacy Predictors of the Third-Line Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase of Chronic Myeloid Leukemia: Results of a Multi-Center Study;Clinical oncohematology;2022

4. Contribution of social and demographic parameters to the long-term survival prognosis of chronic myeloid leukemia patients;Russian journal of hematology and transfusiology;2021-10-25

5. Molecular genetic methods in biomedical research. Part III: human gene diagnostics in clinical practice;Fundamental and Clinical Medicine;2021-09-26